The German evidence-based guidelines for Hodgkin's lymphoma: Aspects for radiation oncologists

Strahlentherapie und Onkologie

Volumn 189, Issue 6, 2013, Pages 445-447

  Eich, H T ^a   Kriz, J ^a   Schmidberger, H ^b   Boll B ^c   Klimm, B ^c   Rancea, M ^c   Muller R P ^c   Engert, A ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chemotherapy; Fluorodeoxyglucose; Positron emission tomography; Radiotherapy; Risk factors

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; DRUG DOSE ESCALATION; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED PRACTICE; HODGKIN DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; EVIDENCE-BASED MEDICINE; FLUORODEOXYGLUCOSE F18; GERMANY; HODGKIN DISEASE; HUMANS; INTERDISCIPLINARY COMMUNICATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOTHERAPY DOSAGE;

EID: 84878293333     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-013-0331-4     Document Type: Article

References (28)

1. Engert A, Franklin J, Eich HT, et al. (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25:3495-3502 (Pubitemid 47310889)
2. Ferme C, Eghbali H, Meerwaldt JH, et al. (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357:1916-1927 (Pubitemid 350074687)
3. Noordijk EM, Carde P, Dupouy N, et al. (2006) Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128-3135 (Pubitemid 46638951)
4. Engert A, Plutschow A, Eich HT, et al. (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652
5. Gordon L, Hong F, Fisher R, et al. (2010) A randomized phase III trial of ABVD vs. Stanford V/+ radiation therapy in locally extensive and advanced stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperatve Oncology Group (E2496) (abstr 6). Blood 116
6. Engert A, Schiller P, Josting A, et al. (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608 (Pubitemid 46594052)
7. Wit M de, Bohuslavizki KH, Buchert R, et al. (2001) 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 12:29-37 (Pubitemid 32162445)
8. Weihrauch MR, Re D, Scheidhauer K, et al. (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98:2930-2934
9. Spaepen K, Stroobants S, Dupont P, et al. (2001) Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272-278 (Pubitemid 34203488)
10. Naumann R, Vaic A, Beuthien-Baumann B, et al. (2001) Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 115:793-800 (Pubitemid 34042895)
11. Sher DJ, Mauch PM, Van Den Abbeele A, et al. (2009) Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol 20:1848-1853
12. Von Tresckow B, Pluetschow A, Fuchs M, et al. (2012) Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Final analysis of the GHSG HD14 Trial. J Clin Oncol 30(9):907-913
13. Eich HT, Diehl V, Gorgen H, et al. (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199-4206
14. Gallamini A, Hutchings M, Rigacci L, et al. (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752 (Pubitemid 47372616)
15. Hutchings M, Loft A, Hansen M, et al. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59 (Pubitemid 43053523)
16. Hutchings M, Mikhaeel NG, Fields PA, et al. (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160-1168 (Pubitemid 41418320)
17. Terasawa T, Lau J, Bardet S, et al. (2009) Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009 27:1906-1914
18. Eich HT, Muller RP, Engenhart-Cabillic R, et al. (2008) Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406-410
19. Girinsky T, Specht L, Ghalibafian M, et al. (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88:202-210
20. Girinsky T, Maazen R van der, Specht L, et al. (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270-277 (Pubitemid 44109907)
21. Engert A, Haverkamp H, Kobe C, et al. (2012) Reduced Intensity of Chemotherapy and PET-giuded Radiotherapy in patients with advanced stage Hodgkin lymphoma: an open-label, randomised phase 3 trial. Lancet 379:1791-1799
22. Aleman BM, Raemaekers JM, Tirelli U, et al. (2003) Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348:2396-2406 (Pubitemid 36682818)
23. Aleman BM, Raemaekers JM, Tomisic R, et al. (2007) Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 67:19-30 (Pubitemid 44959502)
24. Loeffler M, Brosteanu O, Hasenclever D, et al. (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International database on Hodgkin's Disease Overview Study Group. J Clin Oncol 16:818-829 (Pubitemid 28108713)
25. Borchmann P, Haverkamp H, Diehl V, et al. (n d) Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol
26. Kobe C, Dietlein M, Franklin J, et al. (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989-3994
27. Nogova L, Reineke T, Eich HT, et al. (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16:1683-1687 (Pubitemid 41510144)
28. Nogova L, Reineke T, Brillant C, et al. (2008) Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434-439 (Pubitemid 351171696)